The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer


Cite item

Full Text

Abstract

Given the high rate of recurrence of epithelial ovarian cancer after radical treatment is necessary to improve the therapeutic approach to its treatment. New drug of marine origin trabectedin has shown high efficacy in monotherapy and in combination with different cytostatics in the treatment of platinum-sensitive recurrent of ovarian cancer. A randomized trial OVA-301 showed the greatest benefit of a combination of trabectedin with pegylated liposomal doxorubicin in the subgroup of patients with partially platinum-sensitive recurrent of ovarian cancer. Acceptable toxicity profile of the drug, presented mainly neutropenia and transient increase of transaminases, making it promising for further study.

About the authors

M V Cherkasova

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России

Email: m_cherkasova@mail.ru
аспирант каф. онкологии

S V Khokhlova

ФГБУ РОНЦ им. Н.Н.Блохина РАМН

канд. мед. наук, ст. науч. сотр. отд-ния химиотерапии

S V Limareva

ФГБУ РОНЦ им. Н.Н.Блохина РАМН

канд. мед. наук, науч. сотр. отд-ния химиотерапии

I Y Bazaeva

ФГБУ РОНЦ им. Н.Н.Блохина РАМН

аспирант отд-ния химиотерапии

N F Orel

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России

д-р мед. наук, вед. науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина, проф. каф. онкологии ГБОУ ДПО РМАПО

V A Gorbunova

ФГБУ РОНЦ им. Н.Н.Блохина РАМН

д-р мед. наук, проф., зав. отд-нием химиотерапии

I V Poddubnaya

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России

чл.-кор. РАМН, д-р мед. наук, проф., зав. каф. онкологии

References

  1. World cancer report. IARC Sci Publ. Lyon 2008.
  2. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные заболевания в России в 2011 г. (заболеваемость и смертность). М., 2013.
  3. Урманчеева А.Ф., Мешкова И.Е. Вопросы эпидемиологии и диагностики рака яичников. Практич. онкология. 2000; 4: 7–13.
  4. David-Cordonnier M.H, Gajate C, Olmea O et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005; 12: 1201–10.
  5. D'Incalci M, Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9 (8): 2157–63.
  6. Valoti G, Nicoletti M.I, Pellegrino A et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 1977–83.
  7. Hendriks H.R, Fiebig H.H, Giavazzi R et al. High antitumor activity of ET- 743 against human tumor xenografts from melanoma, non - small - cell lung and ovarian cancer. Ann Oncol 1999; 10: 1233–40.
  8. Sessa C, de Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 20: 1867–74.
  9. Krasner C.N, Mc Meekin D.S, Chan S et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum - based regimens. Br J Cancer 2007; 97 (12): 1618–24.
  10. Del Campo J.M, Roszak A, Bidzinski M et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1,5 mg/m2 24h or 1,3 mg/m2 3h) to patients with relapsed, platinum - sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794–802.
  11. Del Campo J.M, Sessa C, Krasner C.N et al. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol 2013; 30: 435.
  12. Ferradina G, Salutari V, Vincenzi B et al. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study. Gynecol Oncol 2013; 130 (3): 505–10.
  13. Petru E, Kolovetsiou V, Idris T. Prolonged response to trabectedin in a patient with ovarian carcinosarcoma refractory to adjuvant platinumtaxane. J Solid Tumors 2013; 3 (3).
  14. Monk B.J, Herzog T, Kaye S et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin versus PLD in relapsed, recurrent ovarian cancer. Proceedings of the 33rd Annual Meeting of the European Society of Medical Oncology. Stockholm 2008. Abstr. LBA3.
  15. Monk B.J, Dalton H, Benjamin I, Tanovi A. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des 2012; 18 (25): 3754–69.
  16. Sehouli J, Alfaro V, Gonzlez-Mart Тn. A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum - sensitive ovarian cancer: current evidence and future perspectives. Ann Oncol 2012; 23 (3): 556–62.
  17. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum - sensitive (platinum - free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2010.
  18. Mabuchi S, Hisamatsu T, Kawase C et al. The activity of Trabectedin as a single agent or in combination with Everolimus for clear cell carcinoma of the ovary. Clin Cancer Res 2011; 17: 4462–73.
  19. Takano M, Ikeda Y, Kudoh K et al. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin. J Obstet Gynaecol Res 2013; 39 (4): 872–5.
  20. Bevacizumab and Trabectedin ± Carboplatin in Advanced Ovarian Cancer Clinical Trials. Identifier: NCT01735071. Mario Negri Institute for Pharmacol Research 2013. Mario Negri Institute for Pharmacological Research. Collaborators: Pharma Mar, Hoffmann-La Roche.
  21. Monk B.J, Sill M, Walker J.L et al. Activity of docetaxel plus trabectedin in reccurent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG). J Clin Oncol 2010; 28 (Suppl. 15): 5046.
  22. Sessa C, Cresta S, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumors. Eur J Cancer 2009; 45: 2116–22.
  23. Sessa C, Gallerani E, Del Conte G et al. Phase I dose - finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol 2011; 29. Abstr. 2517.
  24. Vidal L, Garcia-Martin M, Tan S et al. Phase I combination study of trabectedin and carboplatin in patients with advanced solid tumors. Ann Oncol 2010; 15 (Suppl. 3): 102–1.
  25. Черкасова М.В., Хохлова С.В., Лимарева С.В. и др. Токсичность трабектединсодержащих комбинаций в терапии различных злокачественных новообразований. Соврем. онкология. 2013; 2 (15): 46–50.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies